Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hormone-refractory Prostate Cancer
- Sponsor
- Zealand University Hospital
- Enrollment
- 34
- Locations
- 2
- Primary Endpoint
- Proportion of study participants that complete the study
- Last Updated
- 7 years ago
Overview
Brief Summary
The aim of the present feasibility study of a new short palliative radiotherapy regime that apply to patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominating debilitating symptom. Diffusion weighted magnetic resonance imaging (DWI) will apply to identify both the lesion and the most aggressive part of the lesion. The symptomatic lesions will be treated with a dose of 4 x 5 Gy, while for the most aggressive part of the lesion the dose will be escalated to 4 x 7 Gy using a simultaneous integrated boost (SIB) technique.
Detailed Description
Please refer to uploaded Study Protocol
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with hormone refractory biopsy proven prostate cancer
- •Presenting with a dominating debilitating symptom
- •Expected median survival of 12 months
- •Focal irradiation of lesion is feasible
- •Systemic therapy according to guidelines
- •age ≥18 years
- •Legal capacity, able to understand consequences of the trial
- •Written informed consent
Exclusion Criteria
- •Relevant comorbidity (limiting radiotherapy according to protocol)
- •Prior radiotherapy limitations to administer radiotherapy according to protocol
- •No large metal implants in vicinity of lesion
- •Department dose constraints for normal tissue can't be met
- •Large bony lesions with extensive osseous destruction
- •Patients symptoms do not correlate with MR findings
Outcomes
Primary Outcomes
Proportion of study participants that complete the study
Time Frame: 6 months
Proportion of study participants that complete radiotherapy with ≥ 90% of prescribed dose
Secondary Outcomes
- Response in dominating symptom score (short form McGill pain Questionnaire)(Baseline, 1,3 and 6 months after radiotherapy)
- Acute radiation toxicity score using CTCAE(Baseline, 1,3 and 6 months after radiotherapy)
- Quality of life score using EORTC QLQ-C30(Baseline and 6 months after radiotherapy)